NRXP — NRX Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1719406 ·
Last close
$2.45
Market Cap
$106.07M
52W High
$5.05
52W Low
$1.62
ADV30
1,429,690
Next earnings
2026-11-16

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 1,159,000 285,000 -8,145,000 -2,175,000 27,815,000 19,822,000 29,801,000
Jun 2026 1,101,000 426,000 -6,501,000 -16,520,000 34,160,000 26,686,000 34,330,000
Mar 2026 1,068,000 437,000 -4,748,000 -1,430,000 11,903,000 6,713,000 25,719,000
Dec 2025 983,000 575,000 -4,624,000 360,000 12,956,000 7,797,000 28,893,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-19,774,000
Investing CF
$-3,707,000
Financing CF
$47,257,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.73
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-324,845,000
Inventory
—
Receivables
$206,000
ST Investments
—
EBIT TTM
$-22,336,000
Pretax Income TTM
$-23,480,000
Interest Exp TTM
$1,144,000
Analysts
3

Yahoo Snapshot (yfinance, live)

Total Revenue
$3,394,000
EBITDA
$-19,762,000
Free Cash Flow
$-9,639,625
Enterprise Value
$121,241,768
Total Cash
$26,686,000
Total Debt
$834,000
Shares Out
43,295,767
Trailing EPS
$-0.51
Book Value
$-0.00
ROE
—
ROA
-64.0%
Div Yield
—

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 1,225,000 -16,224,000 -28,622,000 12,956,000 28,893,000 -15,937,000 -14,112,000
Dec 2024 0 -18,502,000 -25,126,000 3,651,000 26,874,000 -23,223,000 -10,637,000
Dec 2023 0 -27,587,000 -30,150,000 7,315,000 19,048,000 -11,733,000 -21,657,000
Dec 2022 0 -44,335,000 -39,754,000 25,816,000 18,407,000 7,409,000 -39,755,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$3,396,000
NetIncome TTM
$-23,479,000
OpCashFlow TTM
—
Assets (Latest)
$34,160,000
Forward EPS
$0.50

Max Pain — expiry 2027-06-17 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.00 · spot: $2.80 · call volume: 4,027 · put volume: 123
Expected Move to 2027-06-17: ±$2.09 (74.64%) — implied range $0.71 – $4.89 · ATM straddle on $2.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
ORGO Organogenesis Holdings Inc. $105.35M $0.81 —
OKUR OnKure Therapeutics, Inc. $104.50M $2.58 —
CATX Perspective Therapeutics, Inc. $103.84M $0.86 —
NERV Minerva Neurosciences, Inc. $103.13M $2.16 —
FHTX Foghorn Therapeutics Inc. $109.73M $1.83 —

News headlines (Yahoo Finance, 1h cache)

NRx (NRXP) Q3 2026 Earnings Call Transcript
2026-11-18 15:29 · Yahoo
What NRx Pharmaceuticals (NRXP) Said on Its Q3 Earnings Call
2026-11-17 15:15 · Yahoo
NRx Pharmaceuticals (Nasdaq: NRXP) Reports Third Quarter 2026 Financial Results and Provides Corporate Update
2026-11-17 12:18 · Yahoo
NRx Pharmaceuticals, Inc. (NRXP) Reports Q3 Loss, Misses Revenue Estimates
2026-11-16 23:00 · Yahoo
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter 2026 Financial Results and Provide Corporate Update
2026-11-12 21:01 · Yahoo
NRx Pharmaceuticals Begins Selling U.S.-Made, Preservative-Free Ketamine Amid Long-Running Shortage
2026-11-11 12:00 · Yahoo
NRx Pharmaceuticals Wins FDA Approval for Preservative-Free Ketamine Injection
2026-10-30 14:14 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
2026-10-30 11:00 · Yahoo
NRx Pharmaceuticals (Nasdaq: NRXP) to Host Conference Call on October 30, 2026 to Discuss Regulatory Milestone for Preservative-Free Ketamine
2026-10-29 20:00 · Yahoo
NRx Pharmaceuticals (Nasdaq:NRXP) Announces Completion of Manufacturing Process Validation and Two-Year Stability of Preservative-Free Ketamine
2026-10-19 12:30 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.